Employees: 985
Size JCR Pharmaceuticals (4552.T) is a Japan Health Care company (Pharmaceuticals: Major) with a market value of $379M, the 1210th largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥496 on 18 Nov 2026.
Performance Over six months the shares fell 5.0%, against -25.1% for the median peer and -1.4% for the Japan market (cap-weighted) — 7th highest of 19 in its peer set.
Growth Revenue grew 3.0% over the last twelve months (peer median -1.1%); the operating margin is -13.8% (peer median -2.2%).
Valuation It trades at 398.3× forward earnings against a peer median of 16.3× (most expensive of 5).
Capital Return on invested capital runs 8.9 points below its cost of capital (5.0% WACC).
Next results Next results expected around 28 Jan 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ¥38.9B | ¥40.3B | ¥33.1B | ¥42.9B | ¥34.3B |
| Revenue growth | — | +22% | -23% | +25% | — |
| Gross profit | ¥27.3B | ¥30.1B | ¥22.0B | ¥31.3B | ¥25.5B |
| EBITDA | -¥3.20B | ¥2.99B | -¥3.04B | ¥10.7B | ¥6.97B |
| Net income | -¥3.40B | ¥2.18B | -¥4.46B | ¥5.51B | ¥3.77B |
| Free cash flow | n/a | -¥11.6B | -¥15.4B | ¥7.79B | -¥13.2B |
| Capital expenditure | n/a | ¥11.6B | ¥9.67B | ¥2.10B | ¥8.56B |
| Total debt | ¥63.7B | ¥54.0B | ¥38.3B | ¥23.4B | ¥22.9B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 4552.T | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -7.1% | -14.0% | 7th highest of 20 |
| 6-month return | -5.0% | -25.1% | 7th highest of 19 |
| Distance from 52-week high | -39.8% | -42.0% | 11th highest of 21 |
| Revenue growth (TTM) | +3.0% | -1.1% | 9th highest of 18 |
| Operating margin | -13.8% | -2.2% | 8th lowest of 19 |
| Forward P/E | 398.3× | 16.3× | most expensive of 5 |
| ROIC minus cost of capital | -8.9 pp | -5.1 pp | 6th lowest of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| JCR Pharmaceuticals 4552.T | Japan | $379M | -5% | +3% | -14% | 398.3× | n/a | n/a |
| Opus Genetics IRD | United States | $379M | -22% | -46% | -778% | n/a | n/a | n/a |
| Jiangsu Bioperfectus Technologies 688399.SS | China | $374M | -51% | -8% | -23% | n/a | n/a | n/a |
| Lifecome Biochemistry 002868.SZ | China | $384M | -54% | -23% | -3% | n/a | n/a | n/a |
| Puma Biotechnology PBYI | United States | $373M | +3% | +9% | 11% | 19.0× | 0.1% | +0.3% |
| SanBio 4592.T | Japan | $386M | -55% | n/a | n/a | n/a | n/a | n/a |
| Gansu Longshenrongfa Pharmaceutical Industry 300534.SZ | China | $386M | -2% | -21% | 8% | n/a | 20.9% | +28.2% |
| Shukra Pharmaceuticals SHUKRAPHAR.NS | India | $387M | n/a | +222% | 54% | n/a | n/a | n/a |
| iX Biopharma 42C.SI | Singapore | $387M | +28% | -12% | -140% | n/a | n/a | n/a |
| ARS Pharmaceuticals SPRY | United States | $371M | -53% | -14% | -162% | n/a | n/a | n/a |
| Avalo Therapeutics AVTX | United States | $387M | -59% | -69% | -161,961% | n/a | n/a | n/a |
| Tiansheng Pharmaceutical 002872.SZ | China | $371M | -1% | -1% | -13% | n/a | 22.2% | -15.7% |
| Anhui Sunhere Pharmaceutical Excipients 300452.SZ | China | $388M | -17% | +9% | 19% | 13.6× | -5.5% | +12.2% |
| MapLight Therapeutics MPLT | United States | $370M | -76% | n/a | n/a | n/a | n/a | n/a |
| 6467 6467.TW | Taiwan | $368M | n/a | n/a | -2,618% | n/a | n/a | n/a |
| Guangdong Lifestrong Pharmacy 301111.SZ | China | $368M | -33% | +7% | -2% | n/a | n/a | n/a |
| Heartseed 219A.T | Japan | $392M | +53% | +197% | 9% | n/a | 46.5% | +73.2% |
| Pharmicell 005690.KS | South Korea | $364M | -55% | +46% | 32% | 8.2× | -7.9% | +24.8% |
| Tuoxin Pharmaceutical 301089.SZ | China | $363M | -28% | +17% | -20% | n/a | n/a | n/a |
| Jiangxi Synergy Pharmaceutical 300636.SZ | China | $398M | -13% | -3% | 2% | 52.7× | 14.9% | +13.7% |
| Unichem Laboratories UNICHEMLAB.NS | India | $361M | +28% | +6% | 5% | n/a | n/a | n/a |